Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-January Through March 2020, 23030-23046 [2020-08719]

Download as PDF 23030 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices Information must be received by June 30, 2020. ADDRESSES: Written comments should be submitted by email to: Opioids_ OlderAdults@abtassoc.com. FOR FURTHER INFORMATION CONTACT: Parivash Nourjah, Parivash.nourjah@ ahrq.gov, or 301–427–1106. SUPPLEMENTARY INFORMATION: The United States is in the midst of an unprecedented opioid epidemic that is affecting people from all walks of life. Regulators and policy makers have initiated many activities to curb the epidemic, but relatively little attention has been paid to the growing toll of opioid use, opioid misuse and opioid use disorder (OUD) among older adults. The opioid crisis in older adults is strongly related to challenges in prescription opioid management in this population. Older adults have a high prevalence of chronic pain and are especially vulnerable to suffering adverse events from opioid use, making safe prescribing more challenging even when opioids are an appropriate therapeutic choice. Identifying adverse effects due to opioid use, misuse or abuse is complicated further by factors such as co-occurring medical disorders that can mimic the effects of opioid use. There is also a risk of attributing clinical findings in older adults (e.g. personality changes, falls/balance problems, difficulty sleeping, and heart problems) to other conditions that are also common with age. If adverse events due to opioid prescriptions are identified, finding appropriate alternatives for pain management can be challenging if other pharmacologic options (such as NSAIDS) are contraindicated or mobility issues limit access to other therapeutic options. Diagnosis of substance use disorders is also more complicated in this population. Clinicians may not associate drug misuse or addiction with older adults or they may be inadequately trained in identification and treatment of opioid misuse and OUD among older adults, and hence may not monitor for the signs of opioid use disorder in this population. Successfully optimizing the prescribing and use of opioids in older adults will require addressing the issue khammond on DSKJM1Z7X2PROD with NOTICES DATES: at many points along the care continuum where older adults may need additional attention or a different approach. AHRQ wants to identify specific tools, strategies and approaches to opioid management in older adults throughout the breadth of the care delivery continuum, from avoiding opioid initiation to screening for opioid misuse and opioid use disorder, as well as approaches to opioid tapering in older adults. AHRQ is interested in all innovative approaches that address the opioid management concerns in older adults listed above, but respondents are welcome to address as many or as few as they choose and to address additional areas of interest not listed. Strategies and approaches could come from a variety of health care settings including, but not limited to, primary care and other ambulatory care clinics, emergency departments, home health care organizations, skilled nursing care settings, and inpatient care. Other sources of these strategies might include health care payers, accountable care organizations, and organizations that provide external quality improvement support. Some of the examples of the types of innovations we are looking for might be specific tools or workflows that support providers to assess the risk/ benefit balance of opioids within a multidisciplinary approach in pain management; to optimize and monitor the opioid prescribing when appropriate, including tapering strategies; to screen and treat for opioid misuse or opioid use disorder; or to involve family or other caregivers of an older adult in conversations about opioid safety. Descriptions of strategies or approaches should include the setting where it is deployed and the type of patient population served. This RFI is for planning purposes only and should not be construed as a policy, solicitation for applications, or as an obligation on the part of the Government to provide support for any ideas in response to it. AHRQ will use the information submitted in response to this RFI at its discretion, and will not provide comments to any respondent’s submission. However, responses to the RFI may be reflected in future solicitation(s) or policies. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. No proprietary, classified, confidential or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). The contents of all submissions will be made available to the public upon request. Submitted materials must be publicly available or able to be made public. Dated: April 21, 2020. Virginia L. Mackay-Smith, Associate Director, Office of the Director, AHRQ. [FR Doc. 2020–08727 Filed 4–23–20; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–9124–N] Medicare and Medicaid Programs; Quarterly Listing of Program Issuances—January Through March 2020 Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: This quarterly notice lists CMS manual instructions, substantive and interpretive regulations, and other Federal Register notices that were published from January through March 2020, relating to the Medicare and Medicaid programs and other programs administered by CMS. FOR FURTHER INFORMATION CONTACT: It is possible that an interested party may need specific information and not be able to determine from the listed information whether the issuance or regulation would fulfill that need. Consequently, we are providing contact persons to answer general questions concerning each of the addenda published in this notice. SUMMARY: Addenda Contact I. CMS Manual Instructions .............................................................................................................. II. Regulation Documents Published in the Federal Register ........................................................ III. CMS Rulings ................................................................................................................................ IV. Medicare National Coverage Determinations ............................................................................. V. FDA-Approved Category B IDEs ................................................................................................. VI. Collections of Information ........................................................................................................... VII. Medicare-Approved Carotid Stent Facilities .............................................................................. Ismael Torres ..................... Terri Plumb ......................... Tiffany Lafferty ................... Wanda Belle, MPA ............. John Manlove ..................... William Parham .................. Sarah Fulton, MHS ............ VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\24APN1.SGM 24APN1 Phone No. (410) (410) (410) (410) (410) (410) (410) 786–1864 786–4481 786–7548 786–7491 786–6877 786–4669 786–2749 23031 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices Addenda Contact VIII. American College of Cardiology-National Cardiovascular Data Registry Sites ....................... IX. Medicare’s Active Coverage-Related Guidance Documents ...................................................... X. One-time Notices Regarding National Coverage Provisions ....................................................... XI. National Oncologic Positron Emission Tomography Registry Sites ........................................... XII. Medicare-Approved Ventricular Assist Device (Destination Therapy) Facilities ....................... XIII. Medicare-Approved Lung Volume Reduction Surgery Facilities .............................................. XIV. Medicare-Approved Bariatric Surgery Facilities ....................................................................... XV. Fluorodeoxyglucose Positron Emission Tomography for Dementia Trials ............................... All Other Information ......................................................................................................................... Sarah Fulton, MHS ............ JoAnna Baldwin, MS .......... JoAnna Baldwin, MS .......... David Dolan, MBA .............. David Dolan, MBA .............. Sarah Fulton, MHS ............ Sarah Fulton, MHS ............ David Dolan, MBA .............. Annette Brewer .................. SUPPLEMENTARY INFORMATION: I. Background khammond on DSKJM1Z7X2PROD with NOTICES The Centers for Medicare & Medicaid Services (CMS) is responsible for administering the Medicare and Medicaid programs and coordination and oversight of private health insurance. Administration and oversight of these programs involves the following: (1) Furnishing information to Medicare and Medicaid beneficiaries, health care providers, and the public; and (2) maintaining effective communications with CMS regional offices, state governments, state Medicaid agencies, state survey agencies, various providers of health care, all Medicare contractors that process claims and pay bills, National Association of Insurance Commissioners (NAIC), health insurers, and other stakeholders. To implement the various statutes on which the programs are based, we issue regulations under the authority granted to the Secretary of the Department of Health and Human Services under sections 1102, 1871, 1902, and related provisions of the Social Security Act (the Act) and Public Health Service Act. We also issue various manuals, memoranda, and statements necessary to administer and oversee the programs efficiently. VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 Section 1871(c) of the Act requires that we publish a list of all Medicare manual instructions, interpretive rules, statements of policy, and guidelines of general applicability not issued as regulations at least every 3 months in the Federal Register. II. Format for the Quarterly Issuance Notices This quarterly notice provides only the specific updates that have occurred in the 3-month period along with a hyperlink to the full listing that is available on the CMS website or the appropriate data registries that are used as our resources. This is the most current up-to-date information and will be available earlier than we publish our quarterly notice. We believe the website list provides more timely access for beneficiaries, providers, and suppliers. We also believe the website offers a more convenient tool for the public to find the full list of qualified providers for these specific services and offers more flexibility and ‘‘real time’’ accessibility. In addition, many of the websites have listservs; that is, the public can subscribe and receive immediate notification of any updates to the website. These listservs avoid the need to check the website, as notification of updates is automatic and PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Phone No. (410) (410) (410) (410) (410) (410) (410) (410) (410) 786–2749 786–7205 786–7205 786–3365 786–3365 786–2749 786–2749 786–3365 786–6580 sent to the subscriber as they occur. If assessing a website proves to be difficult, the contact person listed can provide information. III. How To Use the Notice This notice is organized into 15 addenda so that a reader may access the subjects published during the quarter covered by the notice to determine whether any are of particular interest. We expect this notice to be used in concert with previously published notices. Those unfamiliar with a description of our Medicare manuals should view the manuals at https:// www.cms.gov/manuals. The Director of the Office of Strategic Operations and Regulatory Affairs of the Centers for Medicare & Medicaid Services (CMS), Kathleen Cantwell, having reviewed and approved this document, authorizes Evell J. Barco Holland, who is the Federal Register Liaison, to electronically sign this document for purposes of publication in the Federal Register. Dated: April 15, 2020. Evell J. Barco Holland, Federal Register Liaison, Department of Health and Human Services. BILLING CODE 4120–01–P E:\FR\FM\24APN1.SGM 24APN1 VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.010</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23032 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23033 EN24AP20.011</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.012</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23034 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23035 EN24AP20.013</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.014</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23036 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23037 EN24AP20.015</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.016</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23038 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23039 EN24AP20.017</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.018</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23040 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23041 EN24AP20.019</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.020</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23042 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23043 EN24AP20.021</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices VerDate Sep<11>2014 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 EN24AP20.022</GPH> khammond on DSKJM1Z7X2PROD with NOTICES 23044 VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4725 E:\FR\FM\24APN1.SGM 24APN1 23045 EN24AP20.023</GPH> khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices 23046 Federal Register / Vol. 85, No. 80 / Friday, April 24, 2020 / Notices [FR Doc. 2020–08719 Filed 4–23–20; 8:45 am] BILLING CODE 4120–01–C DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–3390–FN] Medicare Program; Approval of Application by the Accreditation Commission for Healthcare for Initial CMS-Approval of Its Home Infusion Therapy Accreditation Program Centers for Medicare and Medicaid Services, HHS. ACTION: Final notice. AGENCY: This final notice announces our decision to approve the Accreditation Commission for Healthcare for initial recognition as a national accrediting organization for home infusion therapy suppliers that wish to participate in the Medicare program. A home infusion therapy supplier that participates must meet the Medicare conditions for coverage (CfCs). DATES: The approval announced in this final notice is effective April 23, 2020 through April 23, 2024. FOR FURTHER INFORMATION CONTACT: Christina Mister-Ward, (410) 786–2441. Lillian Williams, (410) 786–8636. SUPPLEMENTARY INFORMATION: khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: I. Background Home Infusion therapy (HIT) is a treatment option for Medicare beneficiaries with a wide range of acute and chronic conditions. Section 5012 of the 21st Century Cures Act (Pub. L. 114– 255, enacted December 13, 2016) added section 1861(iii) to the Social Security Act (the Act), establishing a new Medicare benefit for HIT services. Section 1861(iii)(1) of the Act defines HIT as professional services, including nursing services; training and education not otherwise covered under the Durable Medical Equipment (DME) benefit; remote monitoring; and other monitoring services. Home infusion therapy must be furnished by a qualified HIT supplier and furnished in the individual’s home. The individual must: • Be under the care of an applicable provider (that is, physician, nurse practitioner, or physician assistant); and • Have a plan of care established and periodically reviewed by a physician in coordination with the furnishing of home infusion drugs under Part B, that prescribes the type, amount, and duration of infusion therapy services that are to be furnished. VerDate Sep<11>2014 17:03 Apr 23, 2020 Jkt 250001 Section 1861(iii)(3)(D)(i)(III) of the Act requires that a qualified HIT supplier be accredited by an accrediting organization (AO) designated by the Secretary in accordance with section 1834(u)(5) of the Act. Section 1834(u)(5)(A) of the Act identifies factors for designating AOs and in reviewing and modifying the list of designated AOs. These statutory factors are as follows: • The ability of the organization to conduct timely reviews of accreditation applications. • The ability of the organization take into account the capacities of suppliers located in a rural area (as defined in section 1886(d)(2)(D) of the Act). • Whether the organization has established reasonable fees to be charged to suppliers applying for accreditation. • Such other factors as the Secretary determines appropriate. Section 1834(u)(5)(B) of the Act requires the Secretary to designate AOs to accredit HIT suppliers furnishing HIT not later than January 1, 2021. Section 1861(iii)(3)(D) of the Act defines ‘‘qualified home infusion therapy suppliers’’ as being accredited by a CMS-approved AO. In the March 1, 2019 Federal Register, we published a solicitation notice entitled, ‘‘Medicare Program; Solicitation of Independent Accrediting Organizations To Participate in the Home Infusion Therapy Supplier Accreditation Program’’ (84 FR 7057). This notice informed national AOs that accredit HIT suppliers of an opportunity to submit applications to participate in the HIT supplier accreditation program. Complete applications will be considered for the January 1, 2021 designation deadline if received by February 1, 2020. Regulations for the approval and oversight of AOs for HIT organizations are located at 42 CFR part 488, subpart L. The requirements for HIT suppliers are located at 42 CFR part 486, subpart I. II. Approval of Accreditation Organizations Section 1834(u)(5) of the Act and the regulations at § 488.1010 require that our findings concerning review and approval of a national AO’s requirements consider, among other factors, the applying AO’s requirements for accreditation; survey procedures; resources for conducting required surveys; capacity to furnish information for use in enforcement activities; monitoring procedures for provider entities found not in compliance with the conditions or requirements; and PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 ability to provide CMS with the necessary data. Section 488.1020(a) requires that we publish, after receipt of an organization’s complete application, a notice identifying the national accrediting body making the request, describing the nature of the request, and providing at least a 30-day public comment period. In accordance with § 488.1010(d), we have 210 days from the receipt of a complete application to approve or deny the application. III. Provisions of the Proposed Notice In the November 25, 2019 Federal Register (84 FR 64904), we published a proposed notice announcing Accreditation Commission for Health Care’s (ACHC’s) request for initial approval of its Medicare HIT accreditation program. In the November 25, 2019 proposed notice, we detailed our evaluation criteria. Under section 1834(u)(5) the Act and in our regulations at § 488.1010, we conducted a review of ACHC Medicare home infusion accreditation application in accordance with the criteria specified by our regulations, which included, but are not limited to the following: • An onsite administrative review of ACHC’s: (1) Corporate policies; (2) financial and human resources available to accomplish the proposed surveys; (3) procedures for training, monitoring, and evaluation of its home infusion therapy surveyors; (4) ability to investigate and respond appropriately to complaints against accredited home infusion therapies; and (5) survey review and decision-making process for accreditation. • The ability for an ACHC to conduct timely review of accreditation applications. • The ability of an ACHC to take into account the capacities of suppliers located in a rural area. • The comparison of an ACHC’s Medicare home infusion therapy accreditation program standards to our current Medicare home infusion therapy conditions for coverage (CfCs). • ACHC’s survey process to determine the following: ++ The composition of the survey team, surveyor qualifications, and ACHC’s ability to provide continuing surveyor training. ++ ACHC’s processes, including periodic resurvey and the ability to investigate and respond appropriately to complaints against accredited home infusion therapies. ++ Evaluate ACHC’s procedures for monitoring home infusion therapies it has found to be out of compliance with ACHC’s program requirements. E:\FR\FM\24APN1.SGM 24APN1

Agencies

[Federal Register Volume 85, Number 80 (Friday, April 24, 2020)]
[Notices]
[Pages 23030-23046]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-08719]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[CMS-9124-N]


Medicare and Medicaid Programs; Quarterly Listing of Program 
Issuances--January Through March 2020

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This quarterly notice lists CMS manual instructions, 
substantive and interpretive regulations, and other Federal Register 
notices that were published from January through March 2020, relating 
to the Medicare and Medicaid programs and other programs administered 
by CMS.

FOR FURTHER INFORMATION CONTACT: It is possible that an interested 
party may need specific information and not be able to determine from 
the listed information whether the issuance or regulation would fulfill 
that need. Consequently, we are providing contact persons to answer 
general questions concerning each of the addenda published in this 
notice.

----------------------------------------------------------------------------------------------------------------
                   Addenda                                         Contact                          Phone No.
----------------------------------------------------------------------------------------------------------------
I. CMS Manual Instructions..................  Ismael Torres....................................   (410) 786-1864
II. Regulation Documents Published in the     Terri Plumb......................................   (410) 786-4481
 Federal Register.
III. CMS Rulings............................  Tiffany Lafferty.................................   (410) 786-7548
IV. Medicare National Coverage                Wanda Belle, MPA.................................   (410) 786-7491
 Determinations.
V. FDA-Approved Category B IDEs.............  John Manlove.....................................   (410) 786-6877
VI. Collections of Information..............  William Parham...................................   (410) 786-4669
VII. Medicare-Approved Carotid Stent          Sarah Fulton, MHS................................   (410) 786-2749
 Facilities.

[[Page 23031]]

 
VIII. American College of Cardiology-         Sarah Fulton, MHS................................   (410) 786-2749
 National Cardiovascular Data Registry Sites.
IX. Medicare's Active Coverage-Related        JoAnna Baldwin, MS...............................   (410) 786-7205
 Guidance Documents.
X. One-time Notices Regarding National        JoAnna Baldwin, MS...............................   (410) 786-7205
 Coverage Provisions.
XI. National Oncologic Positron Emission      David Dolan, MBA.................................   (410) 786-3365
 Tomography Registry Sites.
XII. Medicare-Approved Ventricular Assist     David Dolan, MBA.................................   (410) 786-3365
 Device (Destination Therapy) Facilities.
XIII. Medicare-Approved Lung Volume           Sarah Fulton, MHS................................   (410) 786-2749
 Reduction Surgery Facilities.
XIV. Medicare-Approved Bariatric Surgery      Sarah Fulton, MHS................................   (410) 786-2749
 Facilities.
XV. Fluorodeoxyglucose Positron Emission      David Dolan, MBA.................................   (410) 786-3365
 Tomography for Dementia Trials.
All Other Information.......................  Annette Brewer...................................   (410) 786-6580
----------------------------------------------------------------------------------------------------------------


SUPPLEMENTARY INFORMATION: 

I. Background

    The Centers for Medicare & Medicaid Services (CMS) is responsible 
for administering the Medicare and Medicaid programs and coordination 
and oversight of private health insurance. Administration and oversight 
of these programs involves the following: (1) Furnishing information to 
Medicare and Medicaid beneficiaries, health care providers, and the 
public; and (2) maintaining effective communications with CMS regional 
offices, state governments, state Medicaid agencies, state survey 
agencies, various providers of health care, all Medicare contractors 
that process claims and pay bills, National Association of Insurance 
Commissioners (NAIC), health insurers, and other stakeholders. To 
implement the various statutes on which the programs are based, we 
issue regulations under the authority granted to the Secretary of the 
Department of Health and Human Services under sections 1102, 1871, 
1902, and related provisions of the Social Security Act (the Act) and 
Public Health Service Act. We also issue various manuals, memoranda, 
and statements necessary to administer and oversee the programs 
efficiently.
    Section 1871(c) of the Act requires that we publish a list of all 
Medicare manual instructions, interpretive rules, statements of policy, 
and guidelines of general applicability not issued as regulations at 
least every 3 months in the Federal Register.

II. Format for the Quarterly Issuance Notices

    This quarterly notice provides only the specific updates that have 
occurred in the 3-month period along with a hyperlink to the full 
listing that is available on the CMS website or the appropriate data 
registries that are used as our resources. This is the most current up-
to-date information and will be available earlier than we publish our 
quarterly notice. We believe the website list provides more timely 
access for beneficiaries, providers, and suppliers. We also believe the 
website offers a more convenient tool for the public to find the full 
list of qualified providers for these specific services and offers more 
flexibility and ``real time'' accessibility. In addition, many of the 
websites have listservs; that is, the public can subscribe and receive 
immediate notification of any updates to the website. These listservs 
avoid the need to check the website, as notification of updates is 
automatic and sent to the subscriber as they occur. If assessing a 
website proves to be difficult, the contact person listed can provide 
information.

III. How To Use the Notice

    This notice is organized into 15 addenda so that a reader may 
access the subjects published during the quarter covered by the notice 
to determine whether any are of particular interest. We expect this 
notice to be used in concert with previously published notices. Those 
unfamiliar with a description of our Medicare manuals should view the 
manuals at https://www.cms.gov/manuals.
    The Director of the Office of Strategic Operations and Regulatory 
Affairs of the Centers for Medicare & Medicaid Services (CMS), Kathleen 
Cantwell, having reviewed and approved this document, authorizes Evell 
J. Barco Holland, who is the Federal Register Liaison, to 
electronically sign this document for purposes of publication in the 
Federal Register.

    Dated: April 15, 2020.
Evell J. Barco Holland,
Federal Register Liaison, Department of Health and Human Services.
BILLING CODE 4120-01-P

[[Page 23032]]

[GRAPHIC] [TIFF OMITTED] TN24AP20.010


[[Page 23033]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.011


[[Page 23034]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.012


[[Page 23035]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.013


[[Page 23036]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.014


[[Page 23037]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.015


[[Page 23038]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.016


[[Page 23039]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.017


[[Page 23040]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.018


[[Page 23041]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.019


[[Page 23042]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.020


[[Page 23043]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.021


[[Page 23044]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.022


[[Page 23045]]


[GRAPHIC] [TIFF OMITTED] TN24AP20.023


[[Page 23046]]


[FR Doc. 2020-08719 Filed 4-23-20; 8:45 am]
 BILLING CODE 4120-01-C

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.